Nicolas Ketterer

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht, Nicolas Mounier, Devinder Gill et al. · Journal of Clinical Oncology · 2010 · 1.6K citations · Full text

Medicine, Oncology, Chemotherapy +13

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 898 citations

Life Sciences, Immunology, Oncology +15

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais et al. · Journal of Clinical Oncology · 2014 · 410 citations · Full text

Medicine, Hematology, Oncology +17

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

Frédéric Garban, Michel Attal, Mauricette Michallet et al. · Blood · 2006 · 370 citations · Full text

Medicine, Hematology, Oncology +16

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman et al. · Journal of Clinical Oncology · 2010 · 334 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17